Nonmyeloablative transplantation studies
| Exp . | Preparative regimen . | n . | Analysis of c-mpl−/− recipients 3 months after transplantation . | |||
|---|---|---|---|---|---|---|
| Blood granulocytes, % donor ± SD . | Marrow granulocytes, % donor ± SD . | Marrow CFU-GMs, % donor ± SD . | Marrow HSCs, % donor ± SD* . | |||
| 1 | AMD3100 | 3 | 26.8 ± 8.0 | 23.5 ± 4.4 | 27.7 ± 7.8 | 5.4 ± 1.6 |
| 2 | Mock rx | 3 | 24.9 ± 8.9 | 16.1 ± 3.8 | 25.1 ± 3.0 | 1.7 ± 0.5 |
| Exp . | Preparative regimen . | n . | Analysis of c-mpl−/− recipients 3 months after transplantation . | |||
|---|---|---|---|---|---|---|
| Blood granulocytes, % donor ± SD . | Marrow granulocytes, % donor ± SD . | Marrow CFU-GMs, % donor ± SD . | Marrow HSCs, % donor ± SD* . | |||
| 1 | AMD3100 | 3 | 26.8 ± 8.0 | 23.5 ± 4.4 | 27.7 ± 7.8 | 5.4 ± 1.6 |
| 2 | Mock rx | 3 | 24.9 ± 8.9 | 16.1 ± 3.8 | 25.1 ± 3.0 | 1.7 ± 0.5 |
The percentage donor (ROSA26) HSCs (∗) was determined by the secondary transplantation of marrow cells into irradiated tpo−/− recipients. See “Results” for details.
rx indicates treatment.